Breakout Setups
NUVL appears in our Breakout Setups screen. This means the stock shows strong technical strength, a constructive consolidation pattern, and enough volatility to support a potential breakout if price moves above resistance.
NUVALENT INC-A (NUVL) Stock Price & Overview
NASDAQ:NUVL • US6707031075
Current stock price
108.02 USD
-0.83 (-0.76%)
At close:
108.02 USD
0 (0%)
After Hours:
The current stock price of NUVL is 108.02 USD. Today NUVL is down by -0.76%. In the past month the price increased by 10.22%. In the past year, price increased by 47.01%.
NUVL Key Statistics
52-Week Range63.555 - 113.015
Current NUVL stock price positioned within its 52-week range.
1-Month Range95.59 - 109.53
Current NUVL stock price positioned within its 1-month range.
- Market Cap
- 8.493B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.85
- Dividend Yield
- N/A
NUVL Stock Performance
Today
-0.76%
1 Week
+4.01%
1 Month
+10.22%
3 Months
+1.48%
Longer-term
6 Months +15.67%
1 Year +47.01%
2 Years +56.82%
3 Years +205.23%
5 Years N/A
10 Years N/A
NUVL Stock Chart
NUVL Stock Screens
NUVL currently appears in the following ChartMill screener lists.
NUVL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to NUVL. When comparing the yearly performance of all stocks, NUVL is one of the better performing stocks in the market, outperforming 79.83% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NUVL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NUVL. No worries on liquidiy or solvency for NUVL as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NUVL Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.58
Revenue Reported
EPS Surprise -4.98%
Revenue Surprise %
NUVL Forecast & Estimates
24 analysts have analysed NUVL and the average price target is 143.16 USD. This implies a price increase of 32.53% is expected in the next year compared to the current price of 108.02.
Analysts
Analysts85.83
Price Target143.16 (32.53%)
EPS Next Y4.55%
Revenue Next YearN/A
NUVL Groups
Sector & Classification
NUVL Financial Highlights
Over the last trailing twelve months NUVL reported a non-GAAP Earnings per Share(EPS) of -5.85. The EPS decreased by -50% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-425.38M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.11% | ||
| ROE | -34.08% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-50.48%
Sales Q2Q%N/A
EPS 1Y (TTM)-50%
Revenue 1Y (TTM)N/A
NUVL Ownership
Ownership
Inst Owners109.17%
Shares78.62M
Float69.48M
Ins Owners0.54%
Short Float %7.16%
Short Ratio9.08
NUVL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.55 | 355.432B | ||
| AMGN | AMGEN INC | 15.27 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 15.12 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.34 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.34 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.97 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.65 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.33 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NUVL
Company Profile
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Company Info
IPO: 2021-07-29
NUVALENT INC-A
One Broadway, 14Th Floor
Cambridge MASSACHUSETTS US
CEO: James R. Porter
Employees: 228
Phone: 13026587581
NUVALENT INC-A / NUVL FAQ
What does NUVALENT INC-A do?
Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2021-07-29. The company develops small molecules that have the potential to overcome resistance, minimize adverse events, and address brain metastases. The company is advancing a robust pipeline with investigational candidates for ROS proto-oncogene 1 (ROS1)-positive, anaplastic lymphoma kinase (ALK)-positive, and human epidermal growth factor receptor 2 (HER2)-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, Zidesamtinib (NVL-520), is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, Neladalkib (NVL-655), is being developed for patients with ALK-positive NSCLC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant HER2-selective inhibitor.
Can you provide the latest stock price for NUVALENT INC-A?
The current stock price of NUVL is 108.02 USD. The price decreased by -0.76% in the last trading session.
Does NUVALENT INC-A pay dividends?
NUVL does not pay a dividend.
How is the ChartMill rating for NUVALENT INC-A?
NUVL has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is NUVALENT INC-A worth?
NUVALENT INC-A (NUVL) has a market capitalization of 8.49B USD. This makes NUVL a Mid Cap stock.
What is the Short Interest ratio of NUVALENT INC-A (NUVL) stock?
The outstanding short interest for NUVALENT INC-A (NUVL) is 7.16% of its float.